Lead by proven industry experience, Marvel is at the forefront of modern science.

Marvel Biosciences is an agile Calgary-based biotechnology company revolutionizing drug development by de-risking the (re)development of existing drugs to create novel therapeutics with enhanced efficacy and safety profiles. We capitalize on modifying known, off-patent drugs to deliver faster, safer, and more effective treatments. Our streamlined approach significantly reduces development costs, shortens timelines, and lowers risk compared to traditional biotech models.

Our lead compound has shown remarkable promise in preclinical studies, demonstrating efficacy for a wide range of conditions, including Alzheimer’s Disease, Depression, Anxiety, and Autism. We are also actively investigating its potential in addressing other neurodevelopmental genetic disorders, such as Rett Syndrome and Fragile X Syndrome, to further expand our therapeutic reach. We have completed cGMP synthesis, toxicology studies, and preparation for Phase 1 clinical trials and are well-positioned to bring our groundbreaking solutions to market.

Marvel Biosciences is a company poised to transform the treatment landscape for multiple high-need indications, tapping into markets with multi-billion dollar potential and minimal competition. Our focus on the A2A adenosine receptor – a target with significant therapeutic promise – sets us apart in our mission to address unmet medical needs.

 Our drug assets are strategically developed to target large and growing markets, addressing significant unmet medical needs across diverse patient populations.

Marvel Biosciences is specifically targeting